Table 2 Reduction in the occurrence of dermatologic changes in dogs with generalized demodicosis after treatment with either Bravecto™ or Advocate®
Bravecto ™ : occurrence of lesions on days before and after treatment (dogs were treated on Day 0: number of dogs/number of dogs per group) | ||||
|---|---|---|---|---|
Clinical sign | Day −4 | Day 28 | Day 56 | Day 84 |
Erythematous patches | 62.5% (5/8) | 37.5% (3/8) | 12.5% (1/8) | 12.5% (1/8) |
Crusts, casts or scales | 100% (8/8) | 62.5% (5/8) | 62.5% (5/8) | 12.5% (1/8) |
Advocate®; occurrence of lesions on days before and after initial treatment (dogs were treated on Days 0, 28 and 56 a : number of dogs/number of dogs per group) | ||||
Clinical sign | Day −4 | Day 28 | Day 56 | Day 84 |
Erythematous patches | 87.5% (7/8) | 50% (4/8) | 0% (0/8) | 0% (0/7)b |
Crusts, casts or scales | 100% (8/8) | 100% (8/8) | 37.5% (3/8) | 42.9% (3/7)b |